A randomized, subject-blind, investigator-blind, placebo-controlled, single-dose, dose escalating study evaluating the safety, pharmacokinetics, and pharmacodynamics of UCB4940 in patients with mild to moderate psoriasis

CB Celltech0 个研究点目标入组 39 人开始时间: 2012年9月21日最近更新: 2017年2月13日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 39

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent form (ICF) is signed and dated by the subject prior to the initiation of any study-specific assessment at Screening.
•2. Subject is considered reliable and capable of adhering to the protocol, according to the judgment of the Investigator, and has adequate reading and writing abilities (in his/her native
•language) such that the subject can comprehend and answer the questions on the subject-completed assessments.
•3. Subject is male or female, aged =18 years to =70 years at Screening. Female subjects must either be postmenopausal (at least 1 year), permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy) or, if of childbearing potential, must be willing to use at least 2 effective methods of contraception, including a barrier method (eg, male condom,
•female condom, or diaphragm with spermicide) during the study period. Effective methods of contraception are methods of birth control, which result in a low failure rate when used consistently and correctly, such as implants, injectables, oral contraceptives,
•progesterone-releasing intrauterine systems or the TCu 380A intrauterine device, complete sexual abstinence, or vasectomized partner (where post vasectomy testing has demonstrated
•sperm clearance). Male subjects with partners of childbearing potential must be willing to use a condom when sexually active. Both male and female subjects must use the above mentioned contraception for 20 weeks after administration of study drug (anticipated 5 half-lives).
•4. Subject has had a confirmed diagnosis of mild to moderate plaque-type psoriasis for at least 6 months involving =5% of BSA (excluding the scalp).
•5. Subject has a body mass index of =35kg/m2 at Screening.
•6. Subject has a minimum of 2 psoriatic lesions with at least 1 plaque in a site suitable for biopsy.
•7. Subject has adequate venous access on inspection.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 19
•1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent form (ICF) is signed and dated by the subject prior to the initiation of any study-specific assessment at Screening.
•2. Subject is considered reliable and capable of adhering to the protocol, according to the judgment of the Investigator, and has adequate reading and writing abilities (in his/her native
•language) such that the subject can comprehend and answer the questions on the subject-completed assessments.
•3. Subject is male or female, aged =18 years to =70 years at Screening. Female subjects must either be postmenopausal (at least 1 year), permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy) or, if of childbearing potential, must be willing to use at least 2 effective methods of contraception, including a barrier method (eg, male condom,
•female condom, or diaphragm with spermicide) during the study period. Effective methods of contraception are methods of birth control, which result in a low failure rate when used consistently and correctly, such as implants, injectables, oral contraceptives,
•progesterone-releasing intrauterine systems or the TCu 380A intrauterine device, complete sexual abstinence, or vasectomized partner (where post vasectomy testing has demonstrated
•sperm clearance). Male subjects with partners of childbearing potential must be willing to use a condom when sexually active. Both male and female subjects must use the above mentioned contraception for 20 weeks after administration of study drug (anticipated 5 half-lives).
•4. Subject has had a confirmed diagnosis of mild to moderate plaque-type psoriasis for at least 6 months involving =5% of BSA (excluding the scalp).
•5. Subject has a body mass index of =35kg/m2 at Screening.
•6. Subject has a minimum of 2 psoriatic lesions with at least 1 plaque in a site suitable for biopsy.
•7. Subject has adequate venous access on inspection.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 19
•1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent form (ICF) is signed and dated by the subject prior to the initiation of any study-specific assessment at Screening.
•2. Subject is considered reliable and capable of adhering to the protocol, according to the judgment of the Investigator, and has adequate reading and writing abilities (in his/her native
•language) such that the subject can comprehend and answer the questions on the subject-completed assessments.
•3. Subject is male or female, aged =18 years to =70 years at Screening. Female subjects must either be postmenopausal (at least 1 year), permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy) or, if of childbearing potential, must be willing to use at least 2 effective methods of contraception, including a barrier method (eg, male condom,
•female condom, or diaphragm with spermicide) during the study period. Effective methods of contraception are methods of birth control, which result in a low failure rate when used consistently and correctly, such as implants, injectables, oral contraceptives,
•progesterone-releasing intrauterine systems or the TCu 380A intrauterine device, complete sexual abstinence, or vasectomized partner (where post vasectomy testing has demonstrated
•sperm clearance). Male subjects with partners of childbearing potential must be willing to use a condom when sexually active. Both male and female subjects must use the above mentioned contraception for 20 weeks after administration of study drug (anticipated 5 half-lives).
•4. Subject has had a confirmed diagnosis of mild to moderate plaque-type psoriasis for at least 6 months involving =5% of BSA (excluding the scalp).
•5. Subject has a body mass index of =35kg/m2 at Screening.
•6. Subject has a minimum of 2 psoriatic lesions with at least 1 plaque in a site suitable for biopsy.
•7. Subject has adequate venous access on inspection.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
另有 1 项未显示

排除标准

•1. Subject has a personal history of polysorbate 80, sorbitol, and/or fructose intolerance.
•2. Subject has donated more than 400mL of blood or blood products within 90 days prior to check-in (Day -2) or plans to donate blood during the study.
•3. Subject is legally institutionalized or has a mental health condition or related care provision (eg, guardianship) that would impede the subject from providing voluntary informed consent to participate in the study.
•4. Subject is an employee or direct relative of an employee of PAREXEL or UCB.
•5. Female subject who is pregnant, or plans to become pregnant during the study, or lactating, or sexually active with childbearing potential who is not using a medically accepted birth control method.
•Exclusion criteria related to drugs:
•6. Subject has received systemic nonbiologic psoriasis therapy (methotrexate [MTX], steroids, cyclophosphamide) or psoralen plus ultraviolet A (PUVA)/ultraviolet A (UVA) phototherapy within 4 weeks prior to Screening.
•7. Subject has received treatment with biologic agents within 12 months prior to the study.
•8. Subject has received live attenuated vaccination within 6 weeks prior to Screening or intends to have such a vaccination during the course of the study.
•9. Subject has received any investigational drug or experimental procedure within 90 days or 5 half-lives, whichever is longer, prior to IMP administration.
•10. Subject has a history of drug allergy or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates his/her participation.
•11. Subject requires treatment with a nonsteroidal anti-inflammatory drug during the study period. Paracetamol will be permitted for use as an antipyretic and/or analgesic.
•Exclusion criteria related to concomitant diseases:
•12. Subject has a current or past history of gastrointestinal ulceration.
•13. Subject has cardiovascular or cerebrovascular disease, including hypertension, angina, ischemic heart disease, transient ischemic attacks, stroke, peripheral arterial disease sufficient to cause symptoms and/or require therapy to maintain stable status.
•14. Subject has diabetes mellitus of any type requiring insulin.
•15. Subject has unstable/poorly-controlled Type 2 diabetes mellitus, defined as a glycosylated hemoglobin type A1c (HbA1c) level =8.5%.
•16. Subject has an active infection (eg, sepsis, pneumonia, abscess) or has had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to IMP administration. When in doubt, the Investigator should confer with the UCB Study Physician.
•17. Subject has a history of a positive tuberculosis (TB) test or evidence of possible TB or latent TB infection at Screening that cannot be attributed to a prior Bacillus Calmette-Guérin
•inoculation.
•18. Subject has a positive hepatitis B surface antigen or positive hepatitis C antibody result within 3 months prior to Screening.
•19. Subject has a positive test for human immunodeficiency virus (HIV) antibody.
•20. Subject has any of the following hematology values at Screening:
•- For women, hemoglobin <11g/dL; for men, <13g/dL
•- ANC <1.5x109/L (<1500/µL)
•21. Subject has 12-lead ECG with changes considered to be clinically significant, eg, QTc >450ms, bundle branch block, evidence of myocardial ischemia.
•22. Subject has renal or liver impairment, defined as:
•- For women, serum creatinine level =125µmol/L; for men, =135µmol/L, or
•- ALT and as;
•1. Subject has a personal history of polysorbate 80, sorbitol, and/or fructose intolerance.
•2. Subject has donated more than 400mL of blood or blood products within 90 days prior to check-in (Day -2) or plans to donate blood during the study.
•3. Subject is legally institutionalized or has a mental health condition or related care provision (eg, guardianship) that would impede the subject from providing voluntary informed consent to participate in the study.
•4. Subject is an employee or direct relative of an employee of PAREXEL or UCB.
•5. Female subject who is pregnant, or plans to become pregnant during the study, or lactating, or sexually active with childbearing potential who is not using a medically accepted birth control method.
•Exclusion criteria related to drugs:
•6. Subject has received systemic nonbiologic psoriasis therapy (methotrexate [MTX], steroids, cyclophosphamide) or psoralen plus ultraviolet A (PUVA)/ultraviolet A (UVA) phototherapy within 4 weeks prior to Screening.
•7. Subject has received treatment with biologic agents within 12 months prior to the study.
•8. Subject has received live attenuated vaccination within 6 weeks prior to Screening or intends to have such a vaccination during the course of the study.
•9. Subject has received any investigational drug or experimental procedure within 90 days or 5 half-lives, whichever is longer, prior to IMP administration.
•10. Subject has a history of drug allergy or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates his/her participation.
•11. Subject requires treatment with a nonsteroidal anti-inflammatory drug during the study period. Paracetamol will be permitted for use as an antipyretic and/or analgesic.
•Exclusion criteria related to concomitant diseases:
•12. Subject has a current or past history of gastrointestinal ulceration.
•13. Subject has cardiovascular or cerebrovascular disease, including hypertension, angina, ischemic heart disease, transient ischemic attacks, stroke, peripheral arterial disease sufficient to cause symptoms and/or require therapy to maintain stable status.
•14. Subject has diabetes mellitus of any type requiring insulin.
•15. Subject has unstable/poorly-controlled Type 2 diabetes mellitus, defined as a glycosylated hemoglobin type A1c (HbA1c) level =8.5%.
•16. Subject has an active infection (eg, sepsis, pneumonia, abscess) or has had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to IMP administration. When in doubt, the Investigator should confer with the UCB Study Physician.
•17. Subject has a history of a positive tuberculosis (TB) test or evidence of possible TB or latent TB infection at Screening that cannot be attributed to a prior Bacillus Calmette-Guérin
•inoculation.
•18. Subject has a positive hepatitis B surface antigen or positive hepatitis C antibody result within 3 months prior to Screening.
另有 37 项未显示

研究者

发起方

CB Celltech

相似试验

进行中（未招募）

1 期

Study of safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in subjects with bronchiectasisMedDRA version: 23.0Level: LLTClassification code 10083611Term: Non-cystic fibrosis bronchiectasisSystem Organ Class: 100000004855Bronchiectasis

EUCTR2019-002840-26-GBovartis Pharma AG72

进行中（未招募）

1 期

Study of LIK066 in overweight and obese women with polycystic ovary syndromepolycystic ovary syndromeMedDRA version: 20.0Level: LLTClassification code 10036050Term: Polycystic ovarySystem Organ Class: 100000004872

EUCTR2017-001373-16-DEovartis Pharma AG29

进行中（未招募）

1 期

EUCTR2019-002840-26-DEovartis Pharma AG72

进行中（未招募）

1 期

Study to assess the efficacy and safety of CJM112 in patients with inadequately controlled severe asthmaInadequately controlled moderate to severe asthmaMedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders

EUCTR2017-000205-21-DKovartis Pharma AG110

进行中（未招募）

1 期

EUCTR2017-000205-21-DEovartis Pharma AG110